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GALA Trial Collaborators. Eur J Vasc Endovasc Surg 2008;36:385-9.
Objective: Recent meta-analyses confirm an advantage to patch
angioplasty during carotid endarterectomy (CEA) and suggest a benefit
from routine shunting. GALA Trial (RCT: general [GA] versus local
[LA] anaesthesia for CEA) collaborators (non-UK [European] and UK)
were surveyed to assess current practice techniques.
Materials and Methods: Postal questionnaires determined: shunt
usage, monitoring techniques dictating shunt deployment, criteria for
patching and the influence of anaesthetic technique upon these decisions.
Results: 157/216 surgeons (73%) replied. For UK surgeons (n 76)
performing GA CEA a shunt was always, never, or selectively used by 73.6%,
4.2% and 22.2% respectively. Figures for non-UK surgeons (n 77) were
20.8% (p 0.0001), 26% (p 0.0002) and 53.2% (p 0.0001).When shunt-
ing selectively, fewer UK surgeons relied on stump pressure (26.4% v 48.1%;
p 0.0064) with TCD more widely used (38.9% v 11.7%; p 0.0001).
Shunting criteria during LA CEA were the same for both groups (impaired
awake-testing). Routine patching was commoner amongst UK surgeons (GA:
76.4% v 34.2%, p 0.0001; LA: 70.1% v 31.9%, p 0.0001).
Conclusions: These results indicate that more UK surgeons have
adopted current suggestions for improving CEA outcomes. Future analysis
of unblinded GALA Trial data may provide further information about the
impact of different policies for shunting and patching.
Is Robotic Surgery Appropriate for Vascular Procedures? Report of
100 Aortoiliac Cases
Štádler P., Dvorˇácˇek L., Vitásek P., Matouš P. Eur J Vasc Endovasc Surg
2008;36:401-9.
Aim:The aim of our study was to evaluate our clinical experience of the
da Vinci™ system for robot-assisted aortoiliac reconstructions to treat oc-
clusive disease and aneurysm.
Material and methods: Between November 2005 and January 2008
100 consecutive patients were scheduled to undergo robot-assisted laparo-
scopic aortoiliac procedures. Patients with serious medical problems and
those who had previously undergone major abdominal surgery were ex-
cluded from the clinical study. Ninety patients were prospectively evaluated
for arterial occlusive disease (AOD), seven patients for abdominal aortic
aneurysms (AAA), two for common iliac artery aneurysms (CIAA) and one
for a combination of CIAA and AOD.
Results:Ninety-seven of 100 procedures (97%) were successfully com-
pleted robotically, while conversions were necessary in three patients (3%).
The median operating time was 235 minutes (range 150 to 360 minutes),
with a median clamp-time of 42 minutes (range 25 to 120 minutes). The
median anastomosis time was 29 minutes (range 12 to 60 minutes) and
median blood loss was 430 mL (range 50 to 1500 mL). The median
intensive care unit stay was 1.7 days and the median hospital stay was 5.1
days. A regular oral diet was resumed after a mean of 2.4 days. Thirty-day
survival was 100% and non-lethal postoperative complications were observed
in three patients (3%).
Conclusions: Robotic aortoiliac surgery appears to be safe, with a high
technical success rate, with operative times and success rates comparable to
conventional open surgery. The creation of the aortoiliac anastomosis
appears to be quicker, and more accurate than regular laparoscopic tech-
niques.
Clinical Endpoints in Peripheral Endovascular Revascularization Tri-
als: a Case for Standardized Definitions
DiehmN., Pattynama P.M., Jaff M.R., Cremonesi A., Becker G.J., Hopkins
L.N., Mahler F., Talen A., Cardella J.F., Ramee S., van Sambeek M.,
Vermassen F., Biamino G. Eur J Vasc Endovasc Surg 2008;36:409-19.
Background: Endovascular therapy is a rapidly expanding option for
the treatment of patients with peripheral arterial disease (PAD), leading to a
myriad of published studies reporting on various revascularization strategies.
However, these reports are often difficult to interpret and compare because
they do not utilize uniform clinical endpoint definitions. Moreover, few of
these studies describe clinical outcomes from a patients’ perspective.Methods and results: The DEFINE Group is a collaborative effort of
an ad-hoc multidisciplinary team from various specialties involved in periph-
eral arterial disease therapy in Europe and the United States. DEFINE’s goal
was to arrive at a broad based consensus for baseline and endpoint definitions
in peripheral endovascular revascularization trials for chronic lower limb
ischemia. In this project, which started in 2006, the individual team mem-
bers reviewed the existing pertinent literature. Following this, a series of
telephone conferences and face-to-face meetings were held to agree upon
definitions. Input was also obtained from regulatory (United States Food
and Drug Administration) and industry (device manufacturers with an
interest in peripheral endovascular revascularization) stakeholders, respec-
tively. The efforts resulted in the current document containing proposed
baseline and endpoint definitions in chronic lower limb PAD. Although the
consensus has inevitably included certain arbitrary choices and compromises,
adherence to these proposed standard definitions would provide consistency
across future trials, thereby facilitating evaluation of clinical effectiveness and
safety of various endovascular revascularization techniques.
Conclusion: This current document is based on a broad based consen-
sus involving relevant stakeholders from the medical community, industry
and regulatory bodies. It is proposed that the consensus document may have
value for study design of future clinical trials in chronic lower limb ischemia
as well as for regulatory purposes.
Ten Years Experience of Treating Aorto-Femoral Bypass Graft Infec-
tion with Venous Allografts
Aavik A., Lieberg J., Kals J., Pulges A., Kals M., Lepner U. Eur J Vasc
Endovasc Surg 2008;36:432-7.
Objective: The aim of the present study was to analyze our results of
treating synthetic vascular graft infection in the aorto-femoral segment with
venous allografts.
Patients and methods: During 1997–2006 we treated 11 male pa-
tients with venous allografts for aorto-femoral segment prosthetic graft
infection. Patients were followed postoperatively with patency assessment
based on Doppler ultrasonography.
Results: The mean interval between the implantation of the syn-
thetic vascular graft and the appearance of infection was 43  29 months
(range 5 months–10 years). Overall primary patency of the venous
allograft was 100%, 88% and 66% at 1, 6 and 36 months, respectively.
Secondary patency rates of the venous allograft were 94% and 73% after 5
and 8 years, respectively. Overall survival rate was 100%, 64%, 46% and
27% after one month, 3, 5 and 8 years, respectively. Limb salvage rate was
100%, 94% and 73% after 1 month, 5 and 8 years, respectively.
Conclusions: The use of in situ venous allograft for the treatment of
synthetic graft infection in the aorto-femoral segment has led to favourable
short- and long-term results.
Negative Pressure Wound Therapy: a Systematic Review on Effective-
ness and Safety
Vikatmaa P., Juutilainen V., Kuukasjärvi P., Malmivaara A. Eur J Vasc
Endovasc Surg 2008;36:438-48.
Objectives:We reviewed the use of negative pressure wound treatment
(NPWT) for problematic wounds.
Methods: A systematic literature review was undertaken to assess the
effectiveness and safety of NPWT. Randomized controlled trials (RCTs)
assessing NPWT were included.
Results: A total of 14 RCTs were included. Trials included patients
with pressure wounds (2), post-traumatic wounds (3), diabetic foot ulcers
(4) and miscellaneous chronic ulcers (5). In all trials NPWT was at least as
effective and in some cases more effective than the control treatment. Most
evidence supports the effectiveness of NPWT on chronic leg ulcers and
posttraumatic ulcers. NPWT appears to be a safe treatment, and serious
adverse events have been rarely reported. Only two trials were classified as
high quality studies, whereas the remaining were classified as having poor
internal validity.
Conclusions:Reliable evidence on the effectiveness of NPWT is scarce.
Tentative evidence indicates that the effectiveness of NPWT is at least as
good as or better than current local treatment for wounds. The need for
large high-quality randomised studies is apparent.
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